Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomes

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Review of Hematology

• Publication date

  2015-09-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/17474086.2015.1071663PMID 26343890
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of adverse events associated with idelalisib treatment: expert panel opinion

  2015influential reference
• Racial/ethnic differences in drug disposition and response: Review of recently approved drugs

  2015cited by this paper
• The biology behind PI3K inhibition in chronic lymphocytic leukaemia

  2015cited by this paper
• Clinical drug interaction profile of idelalisib in healthy subjects

  2015influential reference
• Targeting PI3 kinase in cancer.

  2015cited by this paper
• Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

  2014influential reference
• Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

  2014cited by this paper
• The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014influential reference
• Targeting PI3‐kinase (PI3K), AKT and mTOR axis in lymphoma

  2014cited by this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cited by this paper
• Non-Hodgkin's lymphomas, version 2.2014.

  2014cited by this paper
• Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).

  2014cited by this paper
• Phosphoinositide 3-kinase inhibitors in lymphoma

  2014cited by this paper
• Drug interactions with solid tumour-targeted therapies.

  2014cited by this paper
• CME Information: Follicular lymphoma: 2014 update on diagnosis and management

  2014cited by this paper
• Follicular lymphoma: 2014 update on diagnosis and management

  2014cited by this paper
• Pharmacokinetics, Metabolism and Excretion Of Idelalisib

  2013influential reference
• Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study.

  2013influential reference
• The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment

  2013influential reference
• Targeting B-cell receptor signaling: changing the paradigm.

  2013cited by this paper
• The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells

  2013cited by this paper
• Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

  2013cited by this paper
• The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

  2013influential reference
• Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies

  2013cited by this paper
• Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

  2013influential reference
• Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects

  2013cited by this paper
• Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

  2013cited by this paper
• Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

  2013cited by this paper
• Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

  2013influential reference
• A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  2013cited by this paper
• PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

  2012cited by this paper
• Management of indolent lymphoma: where are we now and where are we going.

  2012cited by this paper
• Akt and mTOR in B Cell Activation and Differentiation

  2012cited by this paper
• PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.

  2011cited by this paper
• Transporter‐Mediated Drug–Drug Interactions

  2011cited by this paper
• The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

  2011cited by this paper
• Transporter-mediated drug-drug interactions.

  2011cited by this paper
• CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

  2011cited by this paper
• Inter-ethnic differences--how important is it in cancer treatment?

  2011cited by this paper
• Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

  2010cited by this paper
• Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

  2010cited by this paper
• The emerging mechanisms of isoform-specific PI3K signalling

  2010cited by this paper
• PI3 kinase signals BCR-dependent mature B cell survival.

  2009cited by this paper
• Phosphoinositide 3-Kinase p110δ Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses1

  2009cited by this paper
• Phosphoinositide 3-Kinase p110 Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses

  2009cited by this paper
• Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

  2008cited by this paper
• Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.

  2006cited by this paper
• Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline

  2006cited by this paper
• Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t

  2005cited by this paper
• Essential, Nonredundant Role for the Phosphoinositide 3-Kinase p110δ in Signaling by the B-Cell Receptor Complex

  2002cited by this paper
• Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.

  2002cited by this paper
• Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice

  2002cited by this paper
• A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and Activation

  2002cited by this paper
• Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

  2001cited by this paper
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

  1997cited by this paper
• A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project

  1997cited by this paper

• Mathematical modelling of oncolytic vaccinia virus therapy highlights neutrophil impact on tumour suppression.

  2025cites this paper
• Induction of Sustained Remissions Associated with Immune Activation by Idelalisib in Patients with Follicular Lymphoma

  2025cites this paper
• Derivative Spectrophotometric Methods for Determination of Idelalisib in Bulk and in Formulation

  2024cites this paper
• Analytical method development, identification, and characterization of stress degradation products of idelalisib by ultrahigh-performance liquid chromatography with photodiode array and ultrahigh-performance liquid chromatography with electrospray ionization quadrupole time-of-flight mass spectromet

  2024cites this paper
• Validated Spectrofluorimetric Method for Estimation of Idelalisib in Bulk and in Formulation

  2023cites this paper
• DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic Study

  2020cites this paper
• Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation

  2020cites this paper
• Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas—Retrospective Analysis of Three Real-Life Clinical Cases—Addressing Issues on Randomization and Customization at the Bedside

  2020cites this paper
• Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?

  2020cites this paper
• Isolation, identification and structural interpretation of degradation impurities in idelalisib

  2020cites this paper
• A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices.

  2019cites this paper
• Characterization of the in vitro metabolites of idelalisib in liver microsomes and interspecies comparison

  2019cites this paper
• Simultaneous determination of idelalisib and its metabolite GS-563117 in dog plasma by LC-MS/MS: Application to a pharmacokinetic study.

  2019cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma

  2019cites this paper
• Follicular Lymphoma: Past, Present, and Future

  2018cites this paper
• Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode

  2018cites this paper
• The possible role of maintenance treatment for primary central nervous system lymphoma.

  2018cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax

  2017cites this paper
• SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.

  2017cites this paper
• Chapter 26 – Idelalisib

  2017cites this paper
• A New World Order in Lymphoma - Checkpoint Inhibitors, Oral Therapies and Maintenance

  2016cites this paper